lucinactant and Meconium-Aspiration-Syndrome

lucinactant has been researched along with Meconium-Aspiration-Syndrome* in 4 studies

Reviews

1 review(s) available for lucinactant and Meconium-Aspiration-Syndrome

ArticleYear
Surfactant lavage therapy for meconium aspiration syndrome: a systematic review and meta-analysis.
    Neonatology, 2012, Volume: 101, Issue:3

    Lung lavage with diluted surfactant has emerged as an innovative treatment for meconium aspiration syndrome (MAS). However, the treatment effect has not yet been fully established.. To investigate the effects of surfactant lavage therapy for MAS by a systematic meta-analysis.. Relevant studies were identified by database searches in MEDLINE (from 1950), EMBASE (from 1980), and CENTRAL, up to June 2010, and by additional hand searches. Meta-analyses were separately conducted for randomized controlled trials (RCTs) and non-randomized controlled studies (NRSs). Risk of bias was assessed and clinical as well as statistical heterogeneities were also investigated in explaining the potential bias.. Two RCTs (87 patients) and eight NRSs (178 patients) were identified. From the results of the meta-analysis of RCTs, surfactant lavage significantly decreased death or the need for extracorporeal membrane oxygenation (RR 0.34, 95% CI 0.11, 0.99). An interventional benefit was indicated for other outcomes, although it was not statistically significant based only on the two RCTs. Results from the analysis of outcomes from NRSs are consistent with those from RCTs and demonstrated a beneficial effect, which could be considered as supporting evidence.. Lung lavage with diluted surfactant appeared to improve the clinical outcome in infants with MAS. Given that less than 100 infants were included in the two RCTs, the findings of this study may still be regarded as insufficient evidence. Further research will be needed to confirm the benefit as well as to refine the lavage technique.

    Topics: Biological Products; Bronchoalveolar Lavage; Drug Combinations; Fatty Alcohols; Humans; Infant, Newborn; Meconium Aspiration Syndrome; Phosphatidylglycerols; Proteins; Pulmonary Surfactants; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome

2012

Other Studies

3 other study(ies) available for lucinactant and Meconium-Aspiration-Syndrome

ArticleYear
Comparative effects of bronchoalveolar lavage with saline, surfactant, or perfluorocarbon in experimental meconium aspiration syndrome.
    Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 2012, Volume: 13, Issue:3

    Today, in meconium aspiration syndrome, treatment focuses on bronchoalveolar lavage, because it removes meconium and proinflammatory factors from airways. This technique might be more effective if different solutions were used such as saline solution, a protein-free surfactant, or a perfluorocarbon, because these would be less inhibited by meconium proteins.. Pulmonary physiology research unit, Cruces Hospital.. Prospective, randomized study.. We studied 24 lambs (<6 days) on mechanical ventilation for 180 mins. Catheters were placed and femoral and pulmonary arteries pressures registered (systemic and pulmonary arterial pressures).. Lambs were instilled with 20% meconium (3-5 mL/Kg) and were randomly assigned to one of the following groups (n = 6): control: only continuous mechanical ventilation; saline bronchoalveolar lavage: bronchoalveolar lavage with 30 mL/kg of saline solution; dilute surfactant bronchoalveolar lavage: bronchoalveolar lavage with 32 mL/kg of diluted surfactant (lucinactant, 10 mg/mL); or perfluorocarbon bronchoalveolar lavage: bronchoalveolar lavage with 30 mL/kg of perfluorocarbon.. Blood gases, cardiovascular parameters, and pulmonary mechanics were assessed. Meconium instillation produced severe hypoxia, hypercapnia, acidosis, and pulmonary hypertension with impairment of pulmonary mechanics (p < .05). Lung lavage with dilute surfactant resulted in the resolution of pulmonary hypertension as well as better gas exchange and pulmonary mechanics than the control group (p < .05). Bronchoalveolar lavage with perfluorocarbon produced a transient improvement in gas exchange and ventilatory indices in comparison with control and saline bronchoalveolar lavage groups.. In lambs with meconium aspiration syndrome, bronchoalveolar lavage with diluted lucinactant is an effective therapy producing significant improvements in gas exchange, pulmonary hypertension, and pulmonary mechanics. In addition, bronchoalveolar lavage with perfluorocarbon appears to confer some advantages over lavage with equal volumes of saline or no lavage.

    Topics: Animals; Bronchoalveolar Lavage; Disease Models, Animal; Drug Combinations; Fatty Alcohols; Fluorocarbons; Humans; Infant, Newborn; Meconium Aspiration Syndrome; Phosphatidylglycerols; Proteins; Pulmonary Surfactants; Random Allocation; Respiration, Artificial; Sheep; Sodium Chloride; Treatment Outcome

2012
Translational research: matching experimental models with therapeutic interventions.
    Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 2012, Volume: 13, Issue:3

    Topics: Animals; Bronchoalveolar Lavage; Drug Combinations; Fatty Alcohols; Fluorocarbons; Humans; Meconium Aspiration Syndrome; Phosphatidylglycerols; Proteins; Pulmonary Surfactants; Sodium Chloride

2012
Bronchoalveolar lavage versus bolus administration of lucinactant, a synthetic surfactant in meconium aspiration in newborn lambs.
    Pediatric pulmonology, 2011, Volume: 46, Issue:10

    This study was designed to study effects of lung lavage versus the classical bolus instillation with a peptide-based synthetic surfactant (lucinactant) in a model of Meconium Aspiration Syndrome (MAS). Eighteen newborn lambs received meconium and were randomized to: the experimental meconium installation (eMAS) group-lambs with eMAS kept on conventional mechanical ventilation (control); the SF-Bolus group-eMAS receiving a lucinactant bolus (30 mg/ml); or the D-SF-Lavage group-eMAS treated with dilute lucinactant bronchoalveolar lavage (10 mg/ml). Systemic and pulmonary arterial pressures, blood gases, and pulmonary mechanics were recorded for 180 min. In addition, the intrapulmonary distribution of the lucinactant was determined using dye-labeled microspheres. Following meconium instillation, severe hypoxia, hypercapnia, acidosis, and pulmonary hypertension developed, and dynamic compliance decreased (50% from baseline). After lung lavage with dilute lucinactant, gas exchange significantly improved versus bolus instillation (P < 0.05). Further, only in the lavage group did pulmonary arterial pressure return to basal values and dynamic compliance significantly increased. Both lung lavage and bolus techniques for the administration of lucinactant resulted in a non-uniform lung distribution. In conclusion, in newborn lambs with respiratory failure and pulmonary hypertension induced by meconium, lung lavage with dilute lucinactant seems to be an effective and safe alternative for treatment for MAS.

    Topics: Animals; Animals, Newborn; Blood Pressure; Bronchoalveolar Lavage; Disease Models, Animal; Drug Combinations; Fatty Alcohols; Humans; Infant, Newborn; Meconium Aspiration Syndrome; Phosphatidylglycerols; Proteins; Pulmonary Surfactants; Respiratory Function Tests; Sheep

2011